Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

This trial is testing amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) — a non-invasive device therapy that uses specific radio wave frequencies — combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for people with newly diagnosed metastatic pancreatic cancer. The device is worn on the body and emits targeted electromagnetic waves that may slow cancer growth. **You may be eligible if...** - You have newly diagnosed, untreated metastatic pancreatic adenocarcinoma (confirmed by biopsy) - You have at least one measurable metastatic tumor on imaging - You are well enough to receive chemotherapy - You agree to use contraception if applicable **You may NOT be eligible if...** - You have received prior treatment for metastatic pancreatic cancer - You have certain implanted devices (e.g., pacemakers) that may be affected by electromagnetic fields - You are pregnant or breastfeeding - You have severe organ dysfunction Talk to your doctor to see if this trial is right for you.